Medical network - on April 14, recently, there are media reports that China enterprise research center of tsinghua university academy of management in collaboration with the daily economic news, study and released the list of 2017 Chinese listed company brand value (including the total list done, overseas plunged, a list of private plunged a list). TOP100 shortlisted for the total list of four of the listed company for medical companies, private plunged a list of finalists have seven pharmaceutical biotechnology company, so, these pharmaceutical enterprise brand value how many money? 

 

Table 1:17 listed Chinese companies list of brand value always done in a list of finalists in pharmaceutical enterprises (unit: one million yuan) 

 

 

Table 17 listed companies in China "brand value list private list plunged a finalist in the pharmaceutical enterprises (unit: one million yuan) 

 

 

Brand value is refers to the brand for the enterprise to bring the current and future excess returns. 

 

It is understood that the activity of the theory and method of evaluation mainly considering the current enterprise financial revenue and brand's contribution to the total revenue ratio for the current benefits for the company, times based on brand earnings outlook future profits from the brand strength, eventually get the brand value. In other words, the enterprise's operating revenues, operating profit growth trend is still an important supporting data reflect the brand value. 

 

From the above two tables we found that the total list of 22 characters holding brand value has exceeded 20 billion yuan, is the most outstanding in the industry; Private list last year listed on the new step pharmaceutical and globalization is done in recent years more and more fire fosun medicine. How they make a high quality brand value? Let's analysis and have a look. 

 

Brand value exceeds 20 billion yuan, sinopharm into industry leader 

 

Figure 1:12-2016 national medicine holding assets (unit: one million yuan) 

 

 

According to the annual report data show that since 2013, the total assets of sinopharm has breached billions of mark, and rising year by year, more than 2016 157.7 billion yuan; Net worth is also rising year by year, in 2016 to 2016 yuan; While the rate of assets and liabilities of the last five years has remained at around 70%. 

 

Figure 12-2016 "national medicine holding revenue situation (unit: one million yuan) 

 

 

From business, since 2014, sinopharm entered the "revenue in 200 billion," 2016 operating income of more than 258.3 billion yuan, up 12.99%; In 2016 net profit more than 2016 yuan, up 20.04% from a year earlier. 

 

As China's largest and most powerful pharmaceutical distribution enterprises, sinopharm both assets and earnings, in recent years has maintained a steady trend. In 2016, sinopharm face adverse macro and industry situation throughout the year, in the key of efficiency structure, to increase quality and promote transformation, further improve the development quality, platform further integration of resources, further play scale effect. Income growth continues to higher than the industry level, profit growth to plunge more than sales growth, further consolidate the industry leading position and advantage. 

 

1, distribution, continue to consolidate the leading status 

 

In the field of medicine distribution, sinopharm has formed an integrated pharmaceutical supply chain, as well as the advanced supply chain management mode, solid variety structure, and continuously optimize the customer structure, national distribution network development and integration. As of December 31, 2016, sinopharm subordinate to China distribution network has covered 31 provinces, municipalities directly under the central government and autonomous regions. Sinopharm direct clients include 14231 hospitals (only refers to the classification of hospital, including the largest highest-level tertiary hospitals, 1991), small end users (including grass-roots medical institutions, etc.), 119931, 79839 retail pharmacies. 

 

Sinopharm said it would continue to intensify efforts to promote the integration of operations, at the same time, we will continue to strengthen the integration of logistics platform construction: the national pharmaceutical logistics distribution network including 4 hub, 38 provincial logistics center, logistics center, 185 city-level logistics network, 24 retail logistics network, the total number of outlets in 251. 

 

2, the rapid growth of retail business 

 

In the field of medicine retail, sinopharm retail to build integrated medicine circulation mode of the structure for the purpose, vigorously promote the development of retail, strengthen the leading edge. Sinopharm in major cities set up directly or join retail pharmacy chains, as of December 31, 2016, stores across the country 18 provinces and cities, with 3502 retail pharmacies (nus pharmacy only belongs), which stores 2503, napa stores 999, rapid sales growth, profitability, scale to maintain the industry leading. 

 

3, the advantage platform to further develop 

 

Advantage, based on a commercial platform, sinopharm continue to push marketing transformation, further explore the marketing innovation service mode of the business, products agency business growth. 

 

Sinopharm actively explore financial capital market, will the transition into the company with integrating new ideas, prompted the company to form a more powerful competitive advantage of industry chain, the rapid growth of the financing lease business profitability increase greatly. Set up its cicc health investment management (Shanghai) co., LTD., industry, capital, distribution, retail industry consolidation, advances the strategy of state-controlled expansion. 

 

On the basis of YaoXie linkage, vigorously develops the washing, disinfection, such as after-sales maintenance hospital medical service, the rapid growth. 

 

To keep up with the trend of "Internet +" seize the medical electrical business development opportunities, promote the fusion of traditional business and the Internet, B2C, O2O business achieved significant growth. 

 

Seize policy opportunities to develop the third party logistics and the integration of cold chain logistics service system, and made good progress. 

 

Listed five months on the list, immediately step pharmaceutical potential is unlimited 

 

Image 14-2016 step pharmaceutical assets situation (unit: one million yuan) 

 

 

On November 8, 2016, step length pharmaceutical success of landing a-share market. According to the latest annual report, according to data from the last three years step pharmaceutical total assets, net assets are rising steadily, total assets of nearly 18.7 billion yuan in 2016, the net worth of more than 12.6 billion yuan. 

 

Figure 4:20 14-2016 step pharmaceutical sales situation (unit: one million yuan) 

 

 

From the point of operating condition, step length pharmaceutical since 2014 to enter the "billions of revenue" legion, operating income slow rise year by year; Net income, because of the company in July 2015, has obtained the pharmaceutical, jilin tonghua GuGong step control of pharmaceutical disposable confirm the non-recurring gains and losses of 1.7 billion yuan, in the net profit growth faster, eliminate these factors, the last three years step pharmaceutical net profit still has good earnings. 

 

Step pharmaceutical major products involves the field of disease of heart head blood-vessel proprietary Chinese medicine, as well as coverage of department of gynaecology medicine and other fields. In 2016 was the first year of the company land capital market, the company adhere to the traditional Chinese medicine (TCM) modernization, relying on the profound historical accumulation and rich in traditional Chinese medicine industry in our country of medicinal materials resources, play to the company in theory, brand, research and development, production and sales of integrated advantage, to further consolidate and strengthen company in heart cerebrovascular and advantages in the field of medicine of department of gynaecology, better finished the production and business operation task, realize the sustained and stable development. 

 

1, the three major varieties of total sales of 9 billion yuan 

 

Heart cerebrovascular medicine field, the step length pharmaceutical, cultivating the heart failure have been successfully developed capsule, metacentric particles and Dan red injection three famous exclusive varieties, the total sales revenue reached 9.006 billion yuan in 2016. 

 

According to m Intranet data show that in 2015 China's urban public hospitals, public hospitals at the county level, community center of cities and towns and townships public medical institutions (hereinafter referred to as China) proprietary Chinese medicine cerebrovascular disease drug product TOP20, Dan red injection ranked second, seventh in the heart failure capsule; In 2015 China's public medical institutions in cardiovascular disease drug product TOP20, metacentric particles ranked eighth. 

 

2, the company has more than 250 national patents 

 

By the end of 2016, the step length pharmaceutical has more than 250 national patents. Heart failure capsule, metacentric particles and Dan red injection are varieties of patent protection, headache ning capsule, capsule, red nucleus fu kang fu phlogistic clean lotion, cream fights capsules and unclogged arteries reserve products such as hypoglycemic capsule also obtained the patent. 

 

It is understood that the company nearly 180 kinds of products in development, along with the further research and development, the company will also have more patent products and exclusive products. Company main product patent expiration time longer, can rule out competitors, master pricing power for a long time. According to these patent products, the company is also in constant research and development of new patents, to extend protection. 

 

3, attaches great importance to the research and development, multi-channel cooperation 

 

Company around the heart head blood-vessel, gynecology, diabetes, especially malignant tumor, digestive system and respiratory system disease treatment field, increase new product development layout. Company in heart cerebrovascular have authoritative expert advisers and cooperation in such fields as scientific research institutions network, improve the efficiency and success rate of new drug research and development. 

 

, in addition, the company extensive industry-university-institute cooperation with domestic and foreign institutions of higher learning, scientific research institutes to cooperate, the introduction of innovative drugs and advanced technology, integration of science and technology, talent and new varieties, to further promote scientific and technological innovation ability. 

 

At the same time, the company is already listed in the varieties also maintained a continuous research and development strength. Launched in 2010, completed in 2012 metacentric particles evidence-based medical research for the company to improve production technology, improve product quality, made a significant contribution to extend the product life cycle. Heart failure, meanwhile, capsule, Dan red injection of evidence-based medicine research also in steady progress, red nucleus fu jie lotion, kang fu phlogistic capsule, headache ning capsule also in continuous secondary development, existing products to mining potential, extend the product life cycle. 

 

2016 is "much starker choices-and graver consequences-in" the start of the implementation of our country, is also a crucial year, to push forward the reform of structural as change unfolds gradually opened, countries intensive in 2016 for the strategic plan for development of Chinese medicine (2016-2030) "and so on a series of health care reform policy and planning, from the supply side, demand side and pay end, respectively, to promote the sustainable and healthy development of the Chinese patent medicine industry in our country, just listed soon step length pharmaceutical potential in the future. 

 

Full medical health industry chain, fosun medicine globalization more walk more 

 

Figure 12-2016 "fosun medicine assets situation (unit: one million yuan) 

 

 

Fosun medicine business areas cover medical health the whole industry chain, business development based on local Chinese and actively for layout of globalization. Assets in recent years, fosun medicine, there is the trend of rising year by year, has total assets of more than 43.7 billion yuan in 2016, the net worth of more than 22.1 billion yuan, asset-liability ratio fell to 42.31%. 

 

Figure 12-2016 fosun medicine revenue situation were disappointed (unit: one million yuan) 

 

 

From business, since 2014, fosun pharma slowing revenue growth, operating income in 2016 to more than 14.6 billion yuan, net profit growth is also slowing, net income of 2.8 billion yuan in 2016. 

 

Fosun medicine said that group to "endogenous growth and denotative expansion" of two-wheel driven strategy, ensure long-term and faster growth. Growth, raw type, with the development of innovative research and development as the core driving factors, and continue to invest in the advantage of curative effect, conform to modern medicine development orientation of product research and development. In terms of denotation expansion, various business sectors are actively seeking perfect product line, expand the market space by means of mergers and acquisitions, and by the depth of the enterprise merger and acquisition integration to reduce costs and improve efficiency, speed up the group the expansion of business scale and improve market competitiveness. 

 

1, the drug manufacturing and research and development is the core of the company sector 

 

In 2016, fosun medicine, cardiovascular system, central nervous system, antitumor treatment fields such as the main core products and antimalarial series such as artesunate, TB series product sales maintained a fast growth; New products and new products, leading in the field of cardiovascular system disease treatment, drying treatment (emperor's), metabolic system in the field of the cloth division he (via optimal state) of the rapid growth of sales. 

 

In 2016, the group a total of 18 preparations item or series of sales over one hundred million yuan, oda gold (calf serum injection to protein), optimal emperor (front row, dry milk), cefmetazole sodium for injection, Rio tinto o moran (reduced glutathione), etc. Series products or sales are more than 500 million yuan. 

 

Fosun medicine said that by the end of 2016, the group in new drug research, generic drugs and biological project 173 items, such as for drugs and vaccines, an application for a patent for drug manufacturing and research and development sectors of 103 items. Group will continue to innovate and to guide, to develop strategic products, and actively seek opportunities for industry mergers and acquisition, integration and coordination of the group of the existing product lines and various resources, actively explore the international market, to expand the size of the group, drug research and development of manufacturing and business to achieve sustained, rapid growth of revenue and profits. 

 

2, build regional medical center, and a big health industry chain 

 

2016, fosun medicine continue to strengthen the basic formation of the coastal developed cities of high-end medical care, second - and third-tier cities specialized subject and the combination of general hospital medical service business strategies, build regional medical center and large health industry chain, to seek and local large state-owned enterprises, public hospitals and university hospital cooperation mode, speed up the development strategy of Internet medical, enhance the business scale and profitability. 

 

In addition, the group will continue to actively support and promote the mutual benefit of its high-end medical service leading brand "united family hospital and clinics" network development and layout. Medical services in the domestic industry at the same time, also pay close attention to the global mainstream medical service and new business model of exploration. 

 

3, medical equipment and medical diagnosis get good grades 

 

In 2016, the group continued to promote their own business in the field of medical instruments and medical diagnosis. Groups continue to strengthen the CML agent high-end medical equipment business to expand, "the Da Vinci surgical robot", as the representative of the minimally invasive surgery with more accurate, small trauma, rapid recovery, and many other advantages, is widely used in urology, thoracic surgery, the treatment of gynecological diseases, its model for continue to achieve rapid growth in 2016. 

 

Company plans through to "the Da Vinci Surgical robot technology and product owner Intuitive Surgical jointly set up a joint venture company, in order to have the aid of Intuitive Surgical leading position in the field of minimally invasive surgery robot technology, and Intuitive Surgical common achieve brand and business concept, resources matching, complementary advantages, promote the group's promotion and development of medical equipment business for high-end medical technology in the development and popularization of China have a positive impact. 

 

conclusion 

 

In recent years, the government level is proposed to speed up cultivating China's famous brands for many times, encourage some good operating performance of enterprises in the global market competition to create excellent brand. The vanguard of the listed companies on behalf of the Chinese economy and energy, in the economic development and market competition, the listed company in a flexible financing channels to win more opportunities, the brand influence of listed companies, in a larger extent, reflects the Chinese enterprises' brand influence. 

 

Rapid growth in recent years, the pharmaceutical industry for China's economic development has brought positive influence is bigger, the government for the development of pharmaceutical industry in China is also constant support and encouragement. We believe that the future will have more drug companies to become the pride of the industry, become the pride of China.